58 related articles for article (PubMed ID: 25847636)
1. Quality-adjusted cost of care: a meaningful way to measure growth in innovation cost versus the value of health gains.
Lakdawalla D; Shafrin J; Lucarelli C; Nicholson S; Khan ZM; Philipson TJ
Health Aff (Millwood); 2015 Apr; 34(4):555-61. PubMed ID: 25847636
[TBL] [Abstract][Full Text] [Related]
2. The Value of the Quality-Adjusted Life Years.
Willke RJ; Pizzi LT; Rand LZ; Neumann P
Value Health; 2024 May; ():. PubMed ID: 38703994
[No Abstract] [Full Text] [Related]
3. Consolidation and maintenance therapy for multiple myeloma after autologous transplantation: where do we stand?
Mohty M; Richardson PG; McCarthy PL; Attal M
Bone Marrow Transplant; 2015 Aug; 50(8):1024-9. PubMed ID: 25893452
[TBL] [Abstract][Full Text] [Related]
4. A cost-effectiveness analysis of real-world treatment for elderly patients with multiple myeloma using a full disease model.
Blommestein HM; Verelst SG; de Groot S; Huijgens PC; Sonneveld P; Uyl-de Groot CA
Eur J Haematol; 2016 Feb; 96(2):198-208. PubMed ID: 25892333
[TBL] [Abstract][Full Text] [Related]
5. Subcutaneous bortezomib in multiple myeloma patients induces similar therapeutic response rates as intravenous application but it does not reduce the incidence of peripheral neuropathy.
Minarik J; Pavlicek P; Pour L; Pika T; Maisnar V; Spicka I; Jarkovsky J; Krejci M; Bacovsky J; Radocha J; Straub J; Kessler P; Wrobel M; Walterova L; Sykora M; Obernauerova J; Brozova L; Gregora E; Adamova D; Gumulec J; Adam Z; Scudla V; Hajek R;
PLoS One; 2015; 10(4):e0123866. PubMed ID: 25875484
[TBL] [Abstract][Full Text] [Related]
6. Cancer mortality reductions were greatest among countries where cancer care spending rose the most, 1995-2007.
Stevens W; Philipson TJ; Khan ZM; MacEwan JP; Linthicum MT; Goldman DP
Health Aff (Millwood); 2015 Apr; 34(4):562-70. PubMed ID: 25847637
[TBL] [Abstract][Full Text] [Related]
7. Bendamustine, thalidomide and dexamethasone combination therapy for relapsed/refractory myeloma patients: results of the MUKone randomized dose selection trial.
Schey S; Brown SR; Tillotson AL; Yong K; Williams C; Davies F; Morgan G; Cavenagh J; Cook G; Cook M; Orti G; Morris C; Sherratt D; Flanagan L; Gregory W; Cavet J;
Br J Haematol; 2015 Aug; 170(3):336-48. PubMed ID: 25891006
[TBL] [Abstract][Full Text] [Related]
8. CD38-Targeted Immunochemotherapy in Refractory Multiple Myeloma: A New Horizon.
Laubach JP; Richardson PG
Clin Cancer Res; 2015 Jun; 21(12):2660-2. PubMed ID: 25878332
[TBL] [Abstract][Full Text] [Related]
9. Autologous stem cell transplantation versus novel drugs or conventional chemotherapy for patients with relapsed multiple myeloma after previous ASCT.
Grövdal M; Nahi H; Gahrton G; Liwing J; Waage A; Abildgaard N; Pedersen PT; Hammerstrøm J; Laaksonen A; Bazia P; Terava V; Ollikainen H; Silvennoinen R; Putkonen M; Anttila P; Porkka K; Remes K
Bone Marrow Transplant; 2015 Jun; 50(6):808-12. PubMed ID: 25867654
[TBL] [Abstract][Full Text] [Related]
10. Safety of outpatient autologous hematopoietic cell transplantation for multiple myeloma and lymphoma.
Graff TM; Singavi AK; Schmidt W; Eastwood D; Drobyski WR; Horowitz M; Palmer J; Pasquini M; Rizzo DJ; Saber W; Hari P; Fenske TS
Bone Marrow Transplant; 2015 Jul; 50(7):947-53. PubMed ID: 25867651
[TBL] [Abstract][Full Text] [Related]
11. Allogeneic stem cell transplantation in multiple myeloma: immunotherapy and new drugs.
Festuccia M; Martino M; Ferrando F; Messina G; Moscato T; Fedele R; Boccadoro M; Giaccone L; Bruno B
Expert Opin Biol Ther; 2015 Jun; 15(6):857-72. PubMed ID: 25865214
[TBL] [Abstract][Full Text] [Related]
12. Data-Driven Technologies as Enablers for Value Creation in the Prevention of Surgical Site Infections: a Systematic Review.
Irgang L; Barth H; Holmén M
J Healthc Inform Res; 2023 Mar; 7(1):1-41. PubMed ID: 36910913
[TBL] [Abstract][Full Text] [Related]
13. A Satellite Account for Health in the United States.
Cutler DM; Ghosh K; Messer KL; Raghunathan T; Rosen AB; Stewart ST
Am Econ Rev; 2022 Feb; 112(2):494-533. PubMed ID: 35529584
[TBL] [Abstract][Full Text] [Related]
14. The value of survival gains from therapeutic innovations for US patients with relapsed/refractory multiple myeloma.
MacEwan JP; Majer I; Chou JW; Panjabi S
Ther Adv Hematol; 2021; 12():20406207211027463. PubMed ID: 34276923
[TBL] [Abstract][Full Text] [Related]
15. On the Anatomy of Medical Progress Within an Overlapping Generations Economy.
Frankovic I; Kuhn M; Wrzaczek S
Economist (Leiden); 2020; 168(2):215-257. PubMed ID: 32624586
[TBL] [Abstract][Full Text] [Related]
16. The changing cost of breast cancer care: lessons from a centralised modern cancer centre.
Joyce DP; O'Neill C; Heneghan HM; Curran C; Barry K; Sweeney K; Malone C; McLaughlin R; Kerin MJ
Ir J Med Sci; 2019 May; 188(2):409-414. PubMed ID: 30032478
[TBL] [Abstract][Full Text] [Related]
17. Temporal Trends in Survival and Healthcare Costs in Patients with Multiple Myeloma in the United States.
Maiese EM; Evans KA; Chu BC; Irwin DE
Am Health Drug Benefits; 2018 Feb; 11(1):39-46. PubMed ID: 29692879
[TBL] [Abstract][Full Text] [Related]
18. Assessing Variation in the Cost of Palivizumab for Respiratory Syncytial Virus Prevention in Preterm Infants.
Shahabi A; Peneva D; Incerti D; McLaurin K; Stevens W
Pharmacoecon Open; 2018 Mar; 2(1):53-61. PubMed ID: 29464672
[TBL] [Abstract][Full Text] [Related]
19. Challenging Perceptions About Oncology Product Pricing in Breast and Colorectal Cancer.
Barron A; Wilsdon T
Pharmaceut Med; 2016; 30(6):321-326. PubMed ID: 27917036
[TBL] [Abstract][Full Text] [Related]
20. Assessment of cost of innovation versus the value of health gains associated with treatment of chronic hepatitis C in the United States: The quality-adjusted cost of care.
Younossi ZM; Park H; Dieterich D; Saab S; Ahmed A; Gordon SC
Medicine (Baltimore); 2016 Oct; 95(41):e5048. PubMed ID: 27741116
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
